Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted first-line treatment and radiotherapy randomization in advanced Hodgkin lymphoma
2008-002684-14Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine and dacarbazine in Hodgkin lymphoma (HL) (3 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: 2-year event-free survival. Started Sep 2008; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2008-002684-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002684-14.